Jolly S R, Kipnis J N, Lucchesi B R
Department of Pharmacology, University of Michigan Medical School, Ann Arbor.
Pharmacology. 1987;35(5):249-55. doi: 10.1159/000138317.
Verapamil-induced cardiovascular depression has been examined in dial-urethane-anesthetized open chest dogs. Verapamil was administered slowly intravenously until the mean arterial pressure was decreased by approximately 45 mm Hg. The dose of verapamil required to reach the hemodynamic endpoint was 1,495 +/- (SE) 165 micrograms/kg. In a second group, interactions between beta-adrenergic blockade, propranolol 1 mg/kg (i.v.), and verapamil were examined. Although propranolol alone had only minor hemodynamic effects, the cardiac depressant dose of verapamil was reduced significantly to 450 +/- 105 micrograms/kg. After cardiovascular depression with verapamil or verapamil plus propranolol, glucagon was administered to assess its inotropic activity using cumulative doses of 5, 15, and 45 micrograms/kg over 20 min. Glucagon produced a dose-dependent recovery of heart rate, mean arterial pressure, and PR interval. Depressed contractility assessed by peak positive dP/dt and right ventricular isometric contractile force also recovered after glucagon. These results suggest a significant interaction between the potency of verapamil as a myocardial depressant and the state of the myocardium as affected by beta-blockade. Cardiac depression by verapamil or verapamil in combination with propranolol was reversible by glucagon.
在使用二乙基亚硝脲麻醉并开胸的犬身上研究了维拉帕米引起的心血管抑制作用。静脉缓慢注射维拉帕米,直至平均动脉压降低约45 mmHg。达到血流动力学终点所需的维拉帕米剂量为1495±(标准误)165微克/千克。在第二组中,研究了β-肾上腺素能阻滞剂普萘洛尔(1毫克/千克,静脉注射)与维拉帕米之间的相互作用。虽然单独使用普萘洛尔只有轻微的血流动力学效应,但维拉帕米的心脏抑制剂量显著降低至450±105微克/千克。在用维拉帕米或维拉帕米加普萘洛尔导致心血管抑制后,给予胰高血糖素,在20分钟内使用5、15和45微克/千克的累积剂量来评估其变力活性。胰高血糖素使心率、平均动脉压和PR间期呈剂量依赖性恢复。通过峰值正dP/dt和右心室等长收缩力评估的收缩力降低在给予胰高血糖素后也恢复了。这些结果表明,维拉帕米作为心肌抑制剂的效力与受β受体阻滞剂影响的心肌状态之间存在显著相互作用。维拉帕米或维拉帕米与普萘洛尔联合引起的心脏抑制可被胰高血糖素逆转。